Wall Street brokerages expect Sensus Healthcare Inc (NASDAQ:SRTS) to post ($0.02) earnings per share (EPS) for the current quarter, Zacks reports. Four analysts have issued estimates for Sensus Healthcare’s earnings, with the lowest EPS estimate coming in at ($0.04) and the highest estimate coming in at $0.00. Sensus Healthcare posted earnings per share of ($0.08) in the same quarter last year, which would indicate a positive year over year growth rate of 75%. The business is expected to issue its next earnings results after the market closes on Thursday, May 9th.
According to Zacks, analysts expect that Sensus Healthcare will report full year earnings of $0.02 per share for the current fiscal year, with EPS estimates ranging from ($0.01) to $0.08. For the next financial year, analysts forecast that the business will report earnings of $0.19 per share, with EPS estimates ranging from $0.01 to $0.32. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that cover Sensus Healthcare.
Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Thursday, February 14th. The company reported $0.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.03. Sensus Healthcare had a negative return on equity of 10.86% and a negative net margin of 7.65%. The business had revenue of $8.08 million during the quarter, compared to analysts’ expectations of $7.33 million.
Shares of SRTS stock traded down $0.11 during mid-day trading on Friday, hitting $6.30. The stock had a trading volume of 5,673 shares, compared to its average volume of 44,929. Sensus Healthcare has a 12-month low of $5.31 and a 12-month high of $9.23. The stock has a market capitalization of $105.80 million, a price-to-earnings ratio of -45.00 and a beta of -0.53.
In other news, EVP Richard Golin sold 5,943 shares of the business’s stock in a transaction that occurred on Wednesday, March 20th. The stock was sold at an average price of $7.56, for a total transaction of $44,929.08. Following the sale, the executive vice president now owns 925,237 shares of the company’s stock, valued at approximately $6,994,791.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 7,203 shares of company stock worth $54,379 in the last three months. Corporate insiders own 41.10% of the company’s stock.
A number of large investors have recently modified their holdings of the stock. Spark Investment Management LLC bought a new stake in Sensus Healthcare during the first quarter worth approximately $155,000. Garrison Bradford & Associates Inc. boosted its holdings in Sensus Healthcare by 275.1% during the first quarter. Garrison Bradford & Associates Inc. now owns 108,400 shares of the company’s stock worth $761,000 after buying an additional 79,500 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Sensus Healthcare by 222.5% during the fourth quarter. Geode Capital Management LLC now owns 45,034 shares of the company’s stock worth $333,000 after buying an additional 31,070 shares in the last quarter. Northern Trust Corp bought a new stake in Sensus Healthcare during the fourth quarter worth approximately $86,000. Finally, BlackRock Inc. boosted its holdings in Sensus Healthcare by 10.2% during the fourth quarter. BlackRock Inc. now owns 26,031 shares of the company’s stock worth $192,000 after buying an additional 2,418 shares in the last quarter. Hedge funds and other institutional investors own 6.51% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Recommended Story: What is the 52-week high/low?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.